期刊文献+

恶性骨肿瘤多药耐药的^(99)Tc^m-MIBI体层显像研究 被引量:3

Research of ^(99)Tc^m-MIBI SPECT imaging for assessment of multidrug resistance in Bone tumor
下载PDF
导出
摘要 大多数肿瘤都有多药耐药-1(MDR-1)基因的过度表达,其表达产物P-糖蛋白(P-gp)在肿瘤的耐药机制中起着关键作用,对P-gp表达的预测在化疗中至关重要,99Tcm-甲氧基异丁基异腈(99Tcm-MIBI)转运分析可作为探测低水平的P-gp表达和定量评价调节转运的敏感指标,指导应用调节剂改善化疗效果。 There has a overexpression ofmultidrug resistance (MDR) gene in most tumor. It is very important that it's expression product P-glycoprotein(P-gp)in multidrug resistance machine of tumor. The anticipation for P-gp expression is significance for chemotherapy. The conveying analysis of ^99Tc^m-sestamibi (^99Tc^m-MIBI) is a sensitiveness index for low-level P-gp expression.
出处 《国外医学(放射医学核医学分册)》 2005年第4期169-170,共2页 Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)
关键词 骨肿瘤 单光子 发射型计算机 体层摄影术 多药耐药 ^99TC^M-甲氧基异丁基异腈 bone tumor single photon emission computed tomography multidrug resistance ^99Tc^m-sestamibi
  • 相关文献

参考文献4

  • 1Baldini N, Scotland K, Scrra M, et al. Adria mycin binding assay;avaluable chemosensitivety test in human ostesarcoma[J]. J Cancer Res Clin Oncol, 1992, 119(1): 121-126.
  • 2Burak Z, Ersoy O, Moretti J, et al. The role of ^99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response[J]. Eur J Nucl Med, 2001, 28(9): 1341-1350.
  • 3Junichi T, Hisashi S, Naohiro A, et al. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy[J]. J Nucl Med, 1998, 39(10): 1179-1184.
  • 4Burak Z, Moretti JL, Ersoy O, et al.^99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein exprenssion [J]. J Nucl Med, 2003, 44(9): 1394-1401.

同被引文献53

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部